MacroGenics announces positive interim Phase 2 LINNET results for lorigerlimab in advanced clear cell gynecologic cancer
MGNX•MGNX•MGNX•MGNX•MacroGenics reported interim Phase 2 LINNET results showing lorigerlimab had a confirmed objective response rate of 25% and disease control rate of 44% in clear cell gynecologic cancer. The company said its safety profile was manageable, dose optimization is ongoing at 3 mg/kg every three weeks, and updated results are expected in the first half of 2027.
MacroGenics said lorigerlimab showed a confirmed objective response rate of 25% and a disease control rate of 44% in advanced clear cell gynecologic cancer in interim Phase 2 LINNET results. The company described the drug’s safety profile as manageable and said dose optimization is ongoing at 3 mg/kg every three weeks.
MacroGenics anticipates sharing updated LINNET results in the first half of 2027.
